Computer Science > Computational Engineering, Finance, and Science
arXiv:2512.17815 (cs)
Abstract:Motivation: The clinical efficacy of antibody therapeutics critically depends on high-affinity target engagement, yet laboratory affinity-maturation campaigns are slow and costly. In computational settings, most protein language models (PLMs) are not trained to favor high-affinity antibodies, and existing preference optimization approaches introduce substantial computational overhead without clear affinity gains. Therefore, this work proposes SimBinder-IF, which converts the inverse folding model ESM-IF into an antibody sequence generator by freezing its structure encod…
Computer Science > Computational Engineering, Finance, and Science
arXiv:2512.17815 (cs)
Abstract:Motivation: The clinical efficacy of antibody therapeutics critically depends on high-affinity target engagement, yet laboratory affinity-maturation campaigns are slow and costly. In computational settings, most protein language models (PLMs) are not trained to favor high-affinity antibodies, and existing preference optimization approaches introduce substantial computational overhead without clear affinity gains. Therefore, this work proposes SimBinder-IF, which converts the inverse folding model ESM-IF into an antibody sequence generator by freezing its structure encoder and training only its decoder to prefer experimentally stronger binders through preference optimization. Results: On the 11-assay AbBiBench benchmark, SimBinder-IF achieves a 55 percent relative improvement in mean Spearman correlation between log-likelihood scores and experimentally measured binding affinity compared to vanilla ESM-IF (from 0.264 to 0.410). In zero-shot generalization across four unseen antigen-antibody complexes, the correlation improves by 156 percent (from 0.115 to 0.294). SimBinder-IF also outperforms baselines in top-10 precision for ten-fold or greater affinity improvements. A case study redesigning antibody F045-092 for A/California/04/2009 (pdmH1N1) shows that SimBinder-IF proposes variants with substantially lower predicted binding free energy changes than ESM-IF (mean Delta Delta G -75.16 vs -46.57). Notably, SimBinder-IF trains only about 18 percent of the parameters of the full ESM-IF model, highlighting its parameter efficiency for high-affinity antibody generation.
| Subjects: | Computational Engineering, Finance, and Science (cs.CE); Biomolecules (q-bio.BM) |
| Cite as: | arXiv:2512.17815 [cs.CE] |
| (or arXiv:2512.17815v1 [cs.CE] for this version) | |
| https://doi.org/10.48550/arXiv.2512.17815 arXiv-issued DOI via DataCite (pending registration) |
Submission history
From: Xinyan Zhao [view email] [v1] Fri, 19 Dec 2025 17:20:05 UTC (2,159 KB)